PDGFRA and gastrointestinal stromal tumor: After first-line imatinib failure, GIST patients are sequentially treated with TKIs such as sunitinib, regorafenib, avapritinib (only for PDGFRA Asp 842 Val-mutant GIST), and ripretinib.18